SCHEMBL17186469

SCHEMBL17186469

Cc1ccc(Cn2c(N)nc3[nH]cnc3c2=O)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SOS1 Q07889 1/20 0.39
▸ P2RX3 P56373 2/20 0.39
▸ PNP P00491 1/20 0.37
▸ POLB P06746 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ RGS12 O14924 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ P2RX7 Q99572 3/20 0.36
▸ PDE5A O76074 2/20 0.35
▸ TYMS P04818 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ DAO P14920 1/20 0.34
▸ MPO P05164 1/20 0.34
▸ TPO P07202 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17186243 0.99 SOS1 (0.39) SOS1P2RX3PNPPOLBKDM4E
SCHEMBL17186356 0.90 PNP (0.39) SOS1PNPUSP2P2RX7CSF1R
Hydrochloric Acid SCHEMBL17186369 0.89 PNP (0.39) SOS1PNPUSP2P2RX7CSF1R
SCHEMBL17186560 0.84 PNP (0.37) SOS1P2RX3PNPPOLBKDM4E
SCHEMBL1533545 0.83 MPO (0.48) PNPPOLBMEN1USP2ALDH1A1
SCHEMBL3303803 0.83 PNP (0.44) PNPPOLBKDM4EMEN1RGS12
Hydrochloric Acid SCHEMBL17186507 0.83 PNP (0.37) SOS1P2RX3PNPPOLBKDM4E
Hydrochloric Acid SCHEMBL17186488 0.82 PNP (0.43) PNPPOLBKDM4EMEN1RGS12
SCHEMBL17186471 0.82 PNP (0.42) SOS1P2RX3PNPPOLBKDM4E
SCHEMBL20970005 0.82 L3MBTL1 (0.44) PNPPOLBKDM4EMEN1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 — — US claimed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 — — EP claimed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 — — WO claimed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 — — EP disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 — — US disclosed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 — — EP disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 SOS1 4702/4885P2RX3 2151/4885PNP 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback